In vitro ELISpot assay verified that TSA-NuTu-Rvaccine could trigger immune defense against OC, and further confirmed that theimmune activity against this tumor was mainly via IFN-γ and IL-4 pathways.Additionally, NK/T cell-mediated cytotoxicity responses by TSA-NuTu-R vaccine playcritical roles in host defenses against tumorigenesis and disease progression. Here, IL4 is linked to neoplasm.